-
Checkpoint inhibitor therapies do not work in about 70% of cancer patients, and even patients who do show an initial response, many suffer a return of the disease. https://buff.ly/3bdu0Cf
#cancer#therapies#checkpoint#inhibitor#epigenetics#oncology$SLRX pic.twitter.com/7zafyWbT0t
-
Since its discovery in 2004, LSD1 has been pursued as an attractive target for cancer treatment. https://buff.ly/2Ba8NbT
#LSD1#checkpoint#inhibitor#cancer#oncology$SLRX pic.twitter.com/901vfVa7oJ
-
-
LSD1 is often highly expressed in advanced metastatic prostate cancer patients, a leading cause of cancer-related deaths with no established cures. https://buff.ly/2Ba8NbT
#LSD1#prostate#cancer#oncology$SLRX pic.twitter.com/kMqB7l7wVZ
-
$SLRX - Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference (Auto:@PJ_Matlock) -
Data Supports Continued Study of Seclidemstat with Checkpoint Inhibitors https://buff.ly/3bdu0Cf
#LSD1#ewingsarcoma#childhood#cancer$SLRX pic.twitter.com/XzdORM5I3s
-
-
-
Salarius
$SLRX Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors https://www.lifesciadvisors.com/news/ -
The Creating Hope Act creates an incentive for companies to develop drugs for pediatric rare diseases: a pediatric priority review voucher. https://buff.ly/2lr3a4C
$SLRX has Priority Review Designation which turns into a Voucher upon approval of Seclidemstat.#childhoodcancerpic.twitter.com/UstWnL6S03
-
Salarius is an early stage biotech with the possibility of near-term inflection points. https://buff.ly/2peDAlg
#ewingsarcoma#childhoodcancer#epigenetics$SLRX pic.twitter.com/PCmTZ7XY99
-
Like any recipe, epigenomes can switch out ingredients without changing genetic codes. Epigenetic illness occurs when the epigenome operates incorrectly or is hijacked. https://buff.ly/2ZpF3W4
#epigenetics#genetic#code#oncology#ewingsarcoma$SLRX pic.twitter.com/FKHTdYwC57
-
Salarius Abstract: Trials in progress: A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma https://buff.ly/2YLk4tV
#epigenetics#epigenetics#symposium#cancer@FoxChaseCancer$SLRX pic.twitter.com/XpvA238d2m
-
Content Carnivores Supporting Clients at Biotech Showcase/JP Morgan Healthcare Conference Week https://buff.ly/2T0V8hn
#biotechshowcase#JPM20$SLRX$GOVX@AqualungCorp@phagomed@Quaralife@pacylex@LachesisBiosci1@Nanovalent_pic.twitter.com/5grEUQ3NkJ
-
News Releases about Biotech Showcase 2020 https://buff.ly/305bVkO
#JPM20#biotechshowcase$SLRX$GOVX@SalariusPharma@Geovax_News@LachesisBiosci1@pacylex@phagomed@quaralife@AqualungCorppic.twitter.com/riNmIj5M5I
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.